pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
povetacicept · news · pharmadog
← back to povetacicept
News mentioning povetacicept
12
stories
1d
Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
biospace
7d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
12d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
15d
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
biopharma dive
Oct 8, 26
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
fiercebiotech
Sep 22, 26
Vertex opens up larger kidney disease opportunity with mid-stage readout
biospace
Sep 11, 26
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
Aug 11, 26
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
Aug 4, 26
Vertex unfazed by competitive IgAN space as FDA verdict looms
biospace
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
May 5, 26
Vertex earnings get muted investor response
biopharma dive